CVAC News and Press, CureVac N.V. From 08/18/22

Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omi...

Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases TÜBINGEN,...

German biotech CureVac N.V. ( NASDAQ: CVAC ) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech ( BNTX ) and U.S. pharma giant ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA") today announced that it has moved to assert its intellectual prop...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

Germany-based biopharma CureVac (NASDAQ:CVAC) will acquire privately held, Amsterdam-based Frame Cancer Therapeutics for €32 million (~$34.3M). Frame is developing personalized oncology immunotherapies and considers its approach neoantigen targeted. In January, Dutch authorities a...

Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting nove...

Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023 Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Develo...

CureVac (NASDAQ:CVAC) has partnered with myNEO to identify specific antigens found on the surface of tumors that can lead to the development of mRNA immunotherapies. Under an agreement, myNEO will use its biological datasets,  machine learning, and bioinformatics platform to identify and...

CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac's mRNA technology with myNEO's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses ...